Trial Profile
Study of the Pharmacokinetics of Golimumab in Moderate to Severe Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Ulcerative colitis
- Focus Pharmacokinetics
- Acronyms GO-KINETIC
- 01 Jun 2019 Status changed to completed.
- 24 Oct 2018 Results assessing faecal loss of goli-mumab (n=3) presented at the 26th United European Gastroenterology Week
- 01 Nov 2017 Results assessing association between systemic exposure of Golimumab during induction therapy and endoscopic response, presented at the 25th United European Gastroenterology Week.